Javelin expands Dyloject deal with Baxter

Javelin Pharmaceuticals has expanded its commercial supply relationship with fellow USA-based Baxter Healthcare. The new agreement relates to Dyloject, Javelin's proprietary injectable diclofenac product currently marketed in the UK and in the second of two pivotal trials in the USA, for acute post-operative pain.

The expanded deal provides additional manufacturing capacity for Dyloject, principally for distribution in the European Union, and builds on the existing manufacturing agreement executed between the companies for the USA.

Dyloject is an injectable non-steroidal anti-inflammatory drug with analgesic, anti-inflammatory and antipyretic activity. Diclofenac, the active ingredient, is a leading analgesic for the treatment of moderate-to-severe postsurgical pain and has demonstrated a history of efficacy and safety since its initial approval in 1981.